SSIR Therapy For Cancer

untitled-35Site Specific Immune Recognition (SSIR) response is the practice of using micro-doses of a commercially available immunization for the purpose of stimulating the immune system to respond with a strong TH1 acute immune reaction in a specific body tissue system where cancer is known to be located.

Dr. Poly Matzinger at the National Institute of Health (NIH) best described this immune response, calling it the “Danger Pattern Driven Tissue Recognition Immune Response.” It was Dr. Hal Gunn in Vancouver, though, who further developed this new paradigm in our understanding of the immune system and called it the “Site Specific Immune Recognition Response.” Dr. Kevin Bethel in Freeport, Bahamas collaborated in this area of immune research through his clinical investigation of the work of Dr. William Coley, eventually leading him to develop SSIR therapy for cancer.

Dr. Coley (1862-1936) created a vaccine of Streptococcus pyogenes and Serratia marcescens produced by Park Davis Pharmaceuticals. Dr. Coley and other doctors, like Dr. Josef Issels (1907-1998), continued to advance the work with Coley’s vaccine. Dr. Bethel recognised that the type of people who best responded to Dr. Coley’s immune therapy were those with cancers involving body tissues that the Streptococcus pyogenes bacteria would normally infect, such as connective tissue (sarcomas) and lymph nodes (lymphomas) and breast ducts (ductal breast cancer).

Dr. Roger Rogers, Dr. Gunn and other doctors at Inspire Health, an integrated cancer care centre in Vancouver, Canada, treated more than 800 cancer patients with killed bacterial immunotherapy treatments since 1982. Dr. Bethel continues to work with Coley’s vaccine produced in Canada by MBVax and several other immune therapies including Qu-Biologics Vaccines. Through the examination of this research, a specific pattern of clinical benefit was noted, leading to the Site-Specific Immunotherapy (SSI) treatment theory. Site-specific in this treatment means therapy specific for the organ and/or tissue affected by the cancer.

A detailed review of the results from treatments of patients with stage 3B lung cancer and stage 4 colon cancer has documented the benefits of SSI therapy. However, formal clinical trials have not been done, though such trials are currently being planned.

While we know that Coley’s vaccine immunotherapy has successfully treated hundreds of patients using various protocols, our aim is to treat cancer through alternative commercial vaccines in a protocol similar to the SSI therapy developed at Inspire Health.

Based on the 100-year knowledge from Coley’s vaccine and other SSI programs developed by Dr. Gunn in Vancouver, it is reasonable that many other commercially available vaccines/immunizations can be used in a site-specific protocol. Dr. Bethel has developed a safe and effective SSIR protocol that combines the experience of current research in this new and promising field of immune medicine.

The SSIR protocol has been used in only a limited number of cancer patients to date, therefore the full side effect profile is unknown. Thus far, no significant side effects have been reported.

Because our immune therapy uses commercial vaccine/immunization preparations already licensed for immunization purposes, it would be expected that a diluted, daily subdermal injection would induce even fewer side effects than full dose administration.

Depending on the locations of the tumour metastasis involvement, Dr. Bethel may choose to combine several other standard commercially available immunizations to further enhance the site-specific immunotherapy nature of the SSIR preparations used to control various cancers. Your SSIR preparation will be individualised in dosage and selection of vaccine/immunization type for your unique cancer situation.

Dr. Bethel is aware of the preliminary nature of the evidence and the investigational nature of SSIRs, but these ‘unknowns’ are offset by the very low cost of the SSIR therapy. They are prepared from already licensed products and have very low risk of side effects or interaction of SSIRs with other standard cancer therapies.

  • For more information on the topic of Site Specific Immune Therapy, visit QuBiologic
  • For more information on the topic of the Danger Model of Immunity and Tissue Pattern Recognition Immunity, click here.
  • For more information on William Coley’s Immune Therapy, click here.